Optimizing skin antisepsis for neonatal surgery: A quality improvement initiative
Topic overview
Quality improvement study demonstrating that chlorhexidine-based skin prep is safe and effective for neonates ≥1500g undergoing surgery, reducing SSI rates from 14% to 8% compared to povidone-iodine. Protocol addresses FDA labeling concerns through weight/age-based concentration selection and validated skin integrity monitoring.
Key takeaways
- 2% CHG-70% IPA is safe for neonates ≥1500g and ≥34 weeks gestational age undergoing abdominal or thoracic surgery.
- CHG-based skin prep reduced SSI rates from 14% to 8% compared to povidone-iodine in matched neonatal surgical cohorts.
- No adverse skin reactions occurred with CHG prep when using validated skin integrity assessment tools in 50 consecutive neonates.
- Gestational age-based CHG concentration protocols (2% vs 0.5%) enable safe antisepsis despite FDA labeling concerns for infants <2 months.
Comments